Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Complete Remission
100%
Newly Diagnosed
100%
Acute Myeloid Leukemia
100%
Venetoclax
100%
FLAG-Ida
100%
Event-free Survival
75%
Overall Survival
75%
Induction Chemotherapy
75%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
75%
Overall Response Rate
50%
Minimal Residual Disease
50%
Hematologic Recovery
50%
Bacteremia
25%
Nonhematologic
25%
Hematological Adverse Events
25%
Partial Response
25%
Leukemia
25%
Granulocyte Colony-stimulating Factor (G-CSF)
25%
Remission Rate
25%
Response Rate
25%
Single Center
25%
Young Patients
25%
Pneumonia
25%
Efficacy Endpoint
25%
Cytarabine
25%
Relapsed or Refractory Acute Myeloid Leukemia
25%
Relapsed or Refractory
25%
Febrile Neutropenia
25%
Treatment Failure
25%
Soft Tissue Infection
25%
Induction Regimen
25%
Idarubicin
25%
Fludarabine
25%
Free State
25%
Credible Interval
25%
Multi-agent
25%
Medicine and Dentistry
Acute Myeloid Leukemia
100%
Venetoclax
100%
Overall Survival
75%
Event Free Survival
75%
Induction Chemotherapy
75%
Minimal Residual Disease
50%
Bacteremia
25%
Adverse Event
25%
Morphology
25%
Leukemia
25%
Cytarabine
25%
Spontaneous Remission
25%
Soft Tissue Infection
25%
Febrile Neutropenia
25%
Granulocyte Colony Stimulating Factor
25%
Idarubicin
25%
Stem Cell Transplant
25%
Fludarabine
25%
Pharmacology, Toxicology and Pharmaceutical Science
Remission
100%
Acute Myeloid Leukemia
100%
Venetoclax
100%
Overall Survival
60%
Chemotherapy
60%
Event Free Survival
60%
Minimal Residual Disease
40%
Adverse Event
20%
Leukemia
20%
Granulocyte Colony Stimulating Factor
20%
Bacteremia
20%
Cytarabine
20%
Febrile Neutropenia
20%
Idarubicin
20%
Fludarabine
20%
Soft Tissue Infection
20%
Biochemistry, Genetics and Molecular Biology
Myeloid
100%
Event Free Survival
75%
Overall Survival
75%
Granulocyte Colony-Stimulating Factor
25%
Morphology
25%
Fludarabine
25%
Cytarabine
25%
Bacteremia
25%
Stem Cell Transplant
25%
Idarubicin
25%